Contract medical research provider Quintiles Transnational Holdingsand health care information company IMS Health Holdings said they would merge in a deal valued at $9 billion.
The combined company, with a market value of nearly $18 billion, will offer drug and medical device makers services ranging from running clinical trials to tracking sales once a product has hit the market.
IMS Health shareholders will receive 0.384 shares of Quintiles for each share held, valuing each IMS Health share at $26.53. IMS Health shares closed at $26.64 on Monday.
